🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

22 recruiting trials

for Moderate Hepatic Impairment

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 NCT07546760Phase 14 sites📍 Chandler📍 Rialto📍 Miami Lakes AstraZeneca · Tests: AZD6234, AZD9550 To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects NCT07480824Phase 12 sites📍 Luoyang📍 Jinan Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ05105 Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment NCT07036133Phase 14 sites📍 Cerritos📍 Chicago📍 Detroit Acrotech Biopharma Inc. · Tests: Pralatrexate Injection A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function NCT07694843Phase 11 site📍 Suzhou CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Tests: ammoxetine hydrochloride enteric-coated tablets Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) NCT06962332Phase 12 sites📍 Orlando📍 San Antonio Exelixis · Tests: Zanzalintinib A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. NCT07401862Phase 13 sites📍 Orlando📍 San Antonio📍 Kistarcsa Eli Lilly and Company · Tests: LY3841136 Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function NCT07751250Phase 11 site📍 San Antonio Arcus Biosciences, Inc. · Tests: Casdatifan Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment NCT07422610Phase 110 sites📍 Bordeaux📍 Saint-Herblain📍 Milan Novartis Pharmaceuticals · Tests: pelabresib Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment NCT04617522Phase 115 sites📍 Long Beach📍 Newark📍 Baltimore Gilead Sciences · Tests: Sacituzumab Govitecan-hziy A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment NCT07165002Phase 13 sites📍 Kistarcsa📍 Auckland📍 Bratislava Eli Lilly and Company · Tests: LY3537031 A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function NCT07231991Phase 14 sites📍 Miami📍 Miami Lakes📍 Orlando Pfizer · Tests: vepdegestrant A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988Phase 252 sites📍 Sarasota📍 Edgewood📍 Lexington AbbVie · Tests: Mirvetuximab Soravtansine A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment NCT07231029Phase 11 site📍 Tokyo Taisho Pharmaceutical Co., Ltd. · Tests: TS-172 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 NCT07844967Phase 11 site📍 Hefei Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: HS-10506 Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment NCT07809802Phase 11 site📍 Changchun Betta Pharmaceuticals Co., Ltd. · Tests: vorolanib, vorolanib, Vorolanib Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment NCT07152288Phase 11 site📍 Beijing Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK39297 tablets, HSK39297 tablets, HSK39297 tablets Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment NCT04953910Phase 122 sites📍 Houston📍 Yerevan📍 Yerevan Taiho Oncology, Inc. · Tests: ASTX727 Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease NCT06825559Phase 11 site📍 Indianapolis Zydus Therapeutics Inc. · Tests: Saroglitazar Magnesium 1 mg A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment NCT07559474Phase 14 sites📍 Chandler📍 Orlando📍 San Antonio Incyte Corporation · Tests: INCB123667 Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants NCT04271488Phase 18 sites📍 Hakata📍 Kurume📍 Yuhu Eisai Co., Ltd. · Tests: Tasurgratinib, Tasurgratinib A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems NCT07023354Phase 14 sites📍 Rialto📍 Orlando📍 Houston Boehringer Ingelheim · Tests: BI 1291583 A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment NCT07343960Phase 12 sites📍 Rialto📍 San Antonio AstraZeneca · Tests: Capivasertib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy